United Therapeutics Corporation

NASDAQ:UTHR

Biotechnology

Healthcare
$577.34 -3.27%

-$18.01 today

Market cap
$24.59B
Beta
0.57
P/E (TTM)
18.0
EPS (TTM)
$29.60
52W Low $272.12High $609.35

Volume 0.42M

Average 0.52M

UTHR EBITDA Margin

EBITDA as a percentage of revenue.

United Therapeutics CorporationNASDAQ: UTHR

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin narrows to 51.0%

EBITDA Margin was 51.0% in Q2 FY2026, down 3.7 pp from a year earlier. On a trailing-twelve-month basis it was 53.1%, down 2.6 pp year over year. Over 3 fiscal years it widened by 3.4 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 10 analysts of 52.0% for the fiscal year ending Dec 2026, down from 57.2% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
51.0%+7.0 pp QoQ
Last fiscal yearDec 2025
57.2%-0.3 pp YoY
LTMJun 2026
53.1%-2.6 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-3.7 pp-9.4 pp-5.8 pp
1 year-0.3 pp-5.1 pp-4.8 pp
3 years+3.4 pp+9.8 pp+6.4 pp
5 years+2.5 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
57.2%
Year-over-year change
-0.3pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How UTHR compares with its peers on the latest reported figures

  • UTHR's LTM Jun 2026 EBITDA Margin of 53.1% is the highest of the 4 companies compared; the peer median is -16.4%.
  • Its year-over-year change of -2.6 pp is the 3rd highest of 4, against a peer median of +167.9 pp.
  • Over three fiscal years its change of +3.4 pp compares with a peer median of +192.5 pp.
UTHR Competitors Peer median
EBITDA Margin for UTHR and competitors
Company Period LTM level YoY 3-year change
UTHRUnited Therapeutics CorporationLTM Jun 202653.1% -2.6 pp+3.4 pp
LQDALiquidia CorporationLTM Jun 202639.4% +670.4 pp+192.5 pp
TVTXTravere Therapeutics, Inc.LTM Sep 2026-16.4% -11.2 pp+278.1 pp
INSMInsmed IncorporatedLTM Jun 2026-67.8% +167.9 pp-10.9 pp
IKTInhibikase Therapeutics, Inc.FY2025— ——
Peer median (excluding UTHR) -16.4%+167.9 pp+192.5 pp

Competitors are the stored peer set for UTHR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.69B1.94B2.33B2.88B3.18B
Cost of Revenue122.5M146.7M257.5M309.7M384.4M
Gross Profit1.56B1.79B2.07B2.57B2.8B
Gross Margin92.7%92.4%88.9%89.2%87.9%
Research & Development540.1M322.9M408M481M550M
Selling, General & Admin467M487M477.1M638.6M731.1M
Operating Expenses1.01B809.9M885.1M1.19B1.28B
Depreciation & Amortization49.9M51.3M53.2M72.5M85.6M
EBITDA736.8M1.04B1.39B1.65B1.82B
EBITDA Margin43.7%53.7%59.6%57.5%57.2%
Operating Income555.9M979.7M1.18B1.38B1.52B
Operating Margin33.0%50.6%50.9%47.9%47.7%
Interest Income16.7M45.2M162.7M199.1M192M
Interest Expense18.6M32.4M59.3M42.9M19.5M
Other Income / Expenses38M(29.1M)89.4M162M196.7M
Income Before Tax593.9M950.6M1.27B1.54B1.71B
Pre-Tax Margin35.2%49.1%54.7%53.5%53.9%
Income Tax Expense118.1M223.3M289.5M343.9M379.2M
Net Income475.8M727.3M984.8M1.2B1.33B
Net Margin28.2%37.6%42.3%41.5%41.9%
EPS (Basic)10.6015.9821.0426.4430.13
EPS (Diluted)10.0615.0019.8124.6427.86
Weighted Avg Shares44.9M45.5M46.8M45.2M44.3M
Weighted Avg Shares (Diluted)47.3M48.5M49.7M48.5M47.9M

United Therapeutics Corporation

NASDAQ:UTHR

Intrinsic Alpha fair value

Locked

Current Price

$577.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.